Stereotaxis to Present at Upcoming Investor Conferences
September 09 2024 - 8:40AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced that David Fischel, Chairman and CEO, will represent
Stereotaxis at two upcoming investor conferences.
- H.C. Wainwright 26th Annual Global
Investment ConferenceMr. Fischel will present an overview of
Stereotaxis business on Wednesday, September
11th, 2024, at 12:30 pm
EST and will be available that same day for one-on-one
meetings.
- Lake Street 8th Annual Best Ideas
Growth ConferenceMr. Fischel will be available for one-on-one
meetings on Thursday, September 12,
2024.
“We appreciate the opportunity to participate in
these conferences and look forward to sharing Stereotaxis'
continued technological, commercial and strategic progress,” says
Mr. Fischel. One-on-one meetings with Mr. Fischel can be arranged
through registration with the conferences.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global
leader in innovative surgical robotics for minimally invasive
endovascular intervention. Its mission is the discovery,
development and delivery of robotic systems, instruments, and
information solutions for the interventional laboratory. These
innovations help physicians provide unsurpassed patient care with
robotic precision and safety, expand access to minimally invasive
therapy, and enhance the productivity, connectivity, and
intelligence in the operating room. Stereotaxis technology has been
used to treat over 100,000 patients across the United States,
Europe, Asia, and elsewhere. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and statements relating to our recent acquisition of
APT, including any benefits expected from the acquisition, and
other risks discussed in the Company's periodic and other filings
with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release. There can be no assurance that the Company will
recognize revenue related to its purchase orders and other
commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Nov 2023 to Nov 2024